Crystalys Therapeutics is a clinical-stage biopharmaceutical company that develops targeted therapies for gout and hyperuricemia.
Crystalys Therapeutics has raised $130.0M in total funding. The most recent round was Series B. The last funding was announced in July 2026.
Crystalys Therapeutics's investors include Wellington Management, Cormorant Asset Management, SR One, Frazier Life Sciences, Novo Holdings.
Crystalys Therapeutics is headquartered in San Diego, United States.
Crystalys Therapeutics is a clinical-stage biopharmaceutical company that develops targeted therapies for gout and hyperuricemia.
Crystalys Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Crystalys Therapeutics — Funding & Investors." VCBacked, July 22, 2026, https://www.vcbacked.co/company/crystalys-therapeutics. Accessed September 15, 2026.
VCBacked. (2026). Crystalys Therapeutics — Funding & Investors. Retrieved September 15, 2026, from https://www.vcbacked.co/company/crystalys-therapeutics
{{cite web |title=Crystalys Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/crystalys-therapeutics |website=VCBacked |access-date=September 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated